These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21535913)

  • 1. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.
    DuBuske LM; Frew AJ; Horak F; Keith PK; Corrigan CJ; Aberer W; Holdich T; von Weikersthal-Drachenberg KJ
    Allergy Asthma Proc; 2011; 32(3):239-47. PubMed ID: 21535913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma.
    Murphy K; Gawchik S; Bernstein D; Andersen J; Pedersen MR
    J Negat Results Biomed; 2013 Jun; 12():10. PubMed ID: 23725348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
    Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
    J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.
    de Kam PJ; Zielen S; Bernstein JA; Berger U; Berger M; Cuevas M; Cypcar D; Fuhr-Horst A; Greisner WA; Jandl M; Laßmann S; Worm M; Matz J; Sher E; Smith C; Steven GC; Mösges R; Shamji MH; DuBuske L; Borghese F; Oluwayi K; Zwingers T; Seybold M; Armfield O; Heath MD; Hewings SJ; Kramer MF; Skinner MA
    Allergy; 2023 Oct; 78(10):2756-2766. PubMed ID: 37366581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis.
    Pfaar O; Lang S; Pieper-Fürst U; Astvatsatourov A; Gerich F; Klimek L; Kramer MF; Reydelet Y; Shah-Hosseini K; Mösges R
    Allergy; 2018 Jan; 73(1):187-195. PubMed ID: 28675499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
    Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
    J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis.
    Ellis AK; Frankish CW; O'Hehir RE; Armstrong K; Steacy L; Larché M; Hafner RP
    J Allergy Clin Immunol; 2017 Aug; 140(2):486-496. PubMed ID: 28236469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.
    Durham SR; Emminger W; Kapp A; de Monchy JG; Rak S; Scadding GK; Wurtzen PA; Andersen JS; Tholstrup B; Riis B; Dahl R
    J Allergy Clin Immunol; 2012 Mar; 129(3):717-725.e5. PubMed ID: 22285278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets.
    Mösges R; Ritter B; Kayoko G; Allekotte S
    Acta Dermatovenerol Alp Pannonica Adriat; 2010 Oct; 19(3):3-10. PubMed ID: 20976414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
    Hordijk GJ; Antvelink JB; Luwema RA
    Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
    Dahl R; Stender A; Rak S
    Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
    Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
    Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
    Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
    J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment.
    Horak F; Jaeger S; Worm M; Melac M; Didier A
    Clin Exp Allergy; 2009 Mar; 39(3):394-400. PubMed ID: 19134018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.
    Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R
    J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: A 3-year randomized placebo-controlled trial.
    Skaarup SH; Schmid JM; Skjold T; Graumann O; Hoffmann HJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):1011-1019. PubMed ID: 32679209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.
    Mösges R; Bachert C; Panzner P; Calderon MA; Haazen L; Pirotton S; Wathelet N; Durham SR; Bonny MA; Legon T; von Frenckell R; Pfaar O; Shamji MH
    Allergy; 2018 Sep; 73(9):1842-1850. PubMed ID: 29512827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.